Chitapanarux, I., Tonusin, A., Sukthomya, V., Charuchinda, C., Pukanhapan, N. and Lorvidhaya, V. (2003) Phase II Clinical Study of Irinotecan and Cisplatin as First-Line Chemotherapy in Metastatic or Recurrent Cervical Cancer. Gynecologic Oncology, 89, 402-407.
http://dx.doi.org/10.1016/S0090-8258(03)00174-4

has been cited by the following article:

• TITLE: The Use of FOLFOX4 Regimen in Stage IV Cervical Cancer: A Pilot Study

  AUTHORS: Ekkasit Tharavichitkul, Ekkapong Tharavichitkul, Somvilai Chakrabandhu, Pitchayaponne Klunklin, Wimrak Onchan, Bongkot Supawongwattana, Nantaka Pukanhaphan, Imjai Chitapanarux

  KEYWORDS: Cervical Cancer, FOLFOX4, Metastasis

  JOURNAL NAME: Journal of Cancer Therapy, Vol.7 No.4, April 28, 2016

  ABSTRACT: Objective: To evaluate the efficacy and safety of FOLFOX4 (oxaliplatin/5FU/Leucovorin) for the treatment of metastatic cervical cancer. Methods: All patients were designed to receive the FOLFOX4 regimen (Oxaliplatin (Eloxatin®) 85 mg/m2 D1, 5-Fluorouracil 400 mg/m2 IV push D1-2, 5-Fluorouracil 600 mg/m2 IV drip in 22 hours D1-2 and Folinic acid 200 mg/m2 IV push in D1-2). The treatment responsiveness and toxicities were evaluated. Results: Thirty patients from January 2010-December 2012 were enrolled into the study. The mean age was 51 years old. Nine patients (31%) achieved objective response. At the mean follow-up time of 13 months, the one-year progression-free and overall survival rates were 20.7% and 65.5%, respectively. The most common grade 3 adverse event reported in this study was anemia (36.7%), thrombocytopenia (16.7%) and fatigue (16.7%). Conclusions: FOLFOX4 regimen in metastatic cervical cancer is feasible.